New Brunswick, New Jersey
December 5, 2002

Senesco Technologies, Inc. ("Senesco" or the "Company") (AMEX:SNT) today announced that David H. Talbot of Melhado Flynn & Associates, Inc. ("Melhado Flynn") has initiated research coverage on the Company. Mr. Talbot is a managing director of Melhado Flynn. Copies of this report can be obtained by contacting Mr. Talbot at:

D.H. Talbot Melhado Flynn & Associates, Inc. 530 Fifth Avenue New York, NY 10036 dtalbot@melhadoflynn.net 212/997-1843 -- fax

Please note that any opinions, estimates or forecasts regarding the Company made by Melhado Flynn & Associates, Inc. are theirs alone and may not represent the opinions, estimates or forecasts of the Company. The Company is providing notice about the availability of the analyst report as a service to its stockholders and is not implying its endorsement of or concurrence with such report. Interested persons must obtain copies of analyst reports on their own; the Company does not distribute analyst reports.

Senesco takes its name from the scientific term for the aging of plant cells: senescence. The Company has developed technology that regulates the onset of cell death. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress for flowers, fruits and vegetables. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has begun to explore ways to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain diseases such as Alzheimer's, glaucoma, ischemia and arthritis, among others. Senesco partners with leading-edge companies and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products. Senesco is headquartered in New Brunswick, New Jersey, and utilizes research laboratories at the University of Waterloo in Ontario, Canada and the  University of Colorado in Denver, Colorado.